Familiar with Company and industry. If they maintain quality focus, trend to outsourcing is no longer a trend; its a business model. Large multiyear contracts are complex with long sales cycle; but once on board, tend to stay. Good recurring revenue model. BR is industry leader, size, breadth of offering, intellectual capital.

Ultimately survives, late to turnaround, but looking smarter. Industry consolidation keeps them in play

Because my boss mentioned it to me one day

Lame China play, but safer than individuals - a long term hold.

I just got out of the hospital - man are we getting old or what! I lost out on Zimmer twice, but MDT is due; plus my broker recommended.

Know this company very well; lab business in general. Strong sales growth is key in this business; recurring revenue through greater number of doctor offices and hospital accounts. After Quest's loss of UHC contract; they may be sniffing around for marketshare. Quest headquarters and BRLI headquarters are communting distance; fold in's are quick and highly accretive in this business.

Why does anybody buy a stock like this; to gamble!

If private money interest continues into biotech; the business savvy will follow. Outsourcing (see BR above) will thrive as Bio-tech firms are mated and forced to work smarter.